...Hello, everybody, and thank you for attending our presentation on AdCOVID, our single-dose intranasal vaccine for COVID-19. My name is Scot Roberts, and I'm the Chief Scientific Officer at Altimmune, and I'm joined today by Dr. Sarah Browne, who heads our clinical vaccine development program. Here's our safe harbor statement. So in addition to a number of clinical stage vaccines that Altimmune is developing using our proprietary intranasal vaccine platform technology, we also have a next-generation peptide therapeutic approach that we're using for both NASH and for hepatitis B. Here's our development pipeline. At the top, you'll see our vaccine indications, including the ongoing Phase I study in COVID-19 with AdCOVID. We've completed Phase I studies with our NasoShield anthrax vaccine, and we've conducted a Phase II study with NasoVAX, our seasonal and pandemic influenza vaccine candidate. In addition, we are developing T-COVID, which is based on the same technology that is being used as...
